A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis

This Study is
No Longer Enrolling

Details
Age

Adult

Type of Study

Treatment

Locations

Outpatient CTRC

Study ID

Protocol Number: 22-1813

More information available at ClinicalTrials.gov: NCT05218096

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers